<p>Artificial intelligence (AI) is increasingly used in mental health, yet its rehabilitation-oriented applications in schizophrenia have not been systematically mapped. We conducted a systematic scoping review of PubMed, Web of Science, IEEE Xplore and the ACM Digital Library (January 1, 2012–October 31, 2025; two search rounds), applying operationalized rehabilitation boundaries and excluding diagnostics-only case–control studies. We extracted data on data sources, feature engineering, model families, validation, calibration, interpretability, application domains, outcomes and implementation readiness. Eighty-three studies met inclusion criteria (median sample size 160; 55% longitudinal). Applications focused on symptom monitoring (48/83), medication management (19/83) and risk management (16/83), whereas functional training (1/83) and psychosocial support (3/83) were rarely targeted. Supervised learning predominated (53/83, 63.9%) over representation learning (20/83, 24%), most commonly using speech/text, electronic health records and smartphone sensing. Across classification tasks, the median AUC was 0.79 (IQR 0.71–0.86); relapse early-warning models showed a median sensitivity of 31.5% at 88.0% specificity. Only four studies reported external validation and three described closed-loop deployment, including one randomized trial that improved adherence. Proxy endpoints were more common than clinical endpoints, and reporting of calibration/uncertainty and fairness auditing was sparse. Overall, AI shows promise for monitoring, adherence support and relapse risk stratification, but routine-care deployment will require externally validated and calibrated human-in-the-loop decision support, privacy-preserving multimodal pipelines and pragmatic trials targeting functional outcomes and participation.</p>